On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Across the recent three months, 12 analysts have shared their insights on Boston Scientific (NYSE: BSX), expressing a variety of opinions spanning from bullish to bearish.
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 20.24%. Currently, Boston Scientific has a market capitalization of $145.17 billion.
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Boston Scientific (BSX) stock shows strong growth, profitability, and a bullish technical setup, making it a top pick for a combined analysis strategy.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Boston Scientific (BSX) is a top technical breakout candidate with strong uptrend momentum and a high-quality consolidation pattern, signaling a potential near-term advance.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Boston Scientific has been treading water for the past six months, recording a small loss of 1.2% while holding steady at $104.10. The stock also fell short of the S&P 500’s 5.5% gain during that period.
